具有高负载的工程葡萄糖反应性胰岛素颗粒,用于长期作用的血糖控制
Dazhi Chen1, Li Yang2,3, Shulan Ni2
1Department of Clinical Medicine, Hangzhou Medical College, Hangzhou, 310053, China.
Advanced materials (Deerfield Beach, Fla.)
|December 17, 2025
概括
研究人员开发了高有效载荷的胰岛素颗粒,可以响应生理变化,延长注射后6天的葡萄糖调节. 这种新型的输送系统为糖尿病管理提供了更安全,更有效的治疗方法.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 内分泌学 在内分泌学.
背景情况:
- 开发高负载药物输送系统对于提高蛋白质疗法的精度,安全性和患者遵守性至关重要.
- 控制这些载体的蛋白质释放以应对生理变化仍然是一个重大挑战.
- 胰岛素 (Ins) 输送需要对血糖波动的动态反应,以有效管理糖尿病.
研究的目的:
- 为持续的葡萄糖管理设计一个对生理学有反应的,高有效载荷的胰岛素颗粒.
- 为了克服传统胰岛素治疗的局限性,例如短时间的作用和频繁的服用.
- 为蛋白质治疗药物开发智能输送系统,以提高安全性和有效性.
主要方法:
- 制造具有高胰岛素负载能力的[Ins&GOx]@Zn]@[TA&Fe]颗粒.
- 在体外和体内对葡萄糖反应性胰岛素释放和降血糖效应的评估.
- 评估长期使用的安全性,包括生理毒性和免疫反应.
主要成果:
- 实现了超过80%的胰岛素负载能力,远远高于之前的报告 (≈40%).
- 一次注射将胰岛素的血糖调节效果从3小时延长到6天.
- 在28天的服用期间,没有显著的生理毒性或免疫反应.
结论:
- 开发的生理学响应,高有效载荷的胰岛素颗粒为长期血糖管理提供了一个有希望的策略.
- 这种方法推动了蛋白质治疗药物的智能输送系统的开发,提高了精度,安全性和患者遵守性.
- 这些工程颗粒代表了朝着更有效,更为患者友好的糖尿病治疗迈出的重要一步.
相关概念视频
Glucagon-like Receptor Agonists
818
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
818
Oral Hypoglycemic Agents: Glinides
565
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
565
Insulin Formulations: Types and Delivery
605
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
605
Insulin: Dosing Regimen and Adverse Effects
656
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
656
Insulin: Biosynthesis, Chemistry, and Preparation
1.2K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.2K
Insulin Secretory Vesicles
6.3K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
6.3K


